Trial Profile
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2022
Price :
$35
*
At a glance
- Drugs Bamlanivimab (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms UNITED
- 16 Mar 2022 Status changed from completed to discontinued.
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 22 Mar 2021 Status changed from recruiting to active, no longer recruiting.